Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.
Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, Bataller A, Charry P, Esteban D, Guijarro F, Jiménez-Vicente C, Castillo-Girón C, Cortes A, Martínez-Roca A, Triguero A, Álamo JR, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: guijarro f. Cancers (Basel). 2022 Aug 25;14(17):4107. doi: 10.3390/cancers14174107. Cancers (Basel). 2022. PMID: 36077644 Free PMC article.
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A, Oñate G, Diaz-Beyá M, Guijarro F, Garrido A, Vives S, Tormo M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldés A, López-Guerra M, Pratcorona M, Zamora L, Villamon E, Roué G, Blanco A, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM). Bataller A, et al. Among authors: guijarro f. Br J Haematol. 2020 Oct;191(1):52-61. doi: 10.1111/bjh.16857. Epub 2020 Jun 8. Br J Haematol. 2020. PMID: 32510599 Free article. Clinical Trial.
KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints.
Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O, Chevallier P, Zaliova M, Zuna J, Mozas P, Magnano L, Grardel N, Cornillet-Lefebvre P, Fu JF, Shih LY, Boneva T, Nacheva E, Beà S, López-Guerra M, Bueno C, Menéndez P, Esteve J, Larghero P, Meyer C, Marschalek R. Bataller A, et al. Among authors: guijarro f. Blood Adv. 2021 Dec 28;5(24):5617-5620. doi: 10.1182/bloodadvances.2021005736. Blood Adv. 2021. PMID: 34638131 Free PMC article. No abstract available.
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
Oliver-Caldes A, Jiménez R, Español-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, Castillo P, Guijarro F, Tovar N, Montoro M, Benitez-Ribas D, Bataller A, González-Navarro EA, Cid J, Lozano M, Perez-Amill L, Martin-Antonio B, Mena MP, Moreno DF, Rodríguez-Lobato LG, Campistol JM, Calvo G, Bladé J, Rosiñol L, Juan M, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldes A, et al. Among authors: guijarro f. J Immunother Cancer. 2021 Dec;9(12):e003783. doi: 10.1136/jitc-2021-003783. J Immunother Cancer. 2021. PMID: 34876408 Free PMC article.
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beyá M, Arnan M, Tormo M, Vives S, de Llano MPQ, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guiñon A, Salamero O, Sampol A, Merchan BM, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldés A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedéu JF, Colomer D, Brunet S, Sierra J, Esteve J. Bataller A, et al. Among authors: guijarro f. Blood Adv. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. Blood Adv. 2022. PMID: 34911079 Free PMC article.
Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan.
Guijarro F, Bataller A, Diaz-Beyá M, Garrido A, Coll-Ferrà C, Vives S, Salamero O, Valcárcel D, Tormo M, Arnan M, Sampol A, Castaño-Díez S, Martínez C, Suárez-Lledó M, Fernández-Avilés F, Hernández-Boluda JC, Ribera JM, Rovira M, Brunet S, Sierra J, Esteve J. Guijarro F, et al. Bone Marrow Transplant. 2022 Aug;57(8):1304-1312. doi: 10.1038/s41409-022-01703-9. Epub 2022 May 28. Bone Marrow Transplant. 2022. PMID: 35643942
42 results